ReviewTherapeutics and clinical risk management2019
Uterine fibroids: an update on current and emerging medical treatment options.
Review in Therapeutics and clinical risk management, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Acupuncture combined with Chinese herbs versus Chinese herbs alone to improve the clinical efficacy of uterine fibroids: a systematic review and meta-analysis.Frontiers in oncology · 2024Pooled it
- Insights on Medical Therapy for Uterine Fibroids: A Review.Advances in therapy · 2026Review
- Preclinical research platform for uterine leiomyoma: construction optimization and selection of animal models.Frontiers in veterinary science · 2026Article
- Pharmacological activities ofFrontiers in pharmacology · 2026Article
- Illuminating the Intricacies: A Comparative Cross-Sectional Sonographic Evaluation of Degenerative Changes in Leiomyomas Through Post-Processing Technique.Diagnostics (Basel, Switzerland) · 2025Article
- The stem bark decoction of Myrianthus arboreus P. Beauv. (Cecropiaceae) shows anti-uterine leiomyoma effects in Wistar rat.Reproduction & fertility · 2025Article
- Laparoscopic myomectomy without uterine manipulator for maintaining endometrial cavity integrity.Heliyon · 2024Article
- Appropriateness of Hysterectomy as Treatment for Benign Gynecological Conditions.Journal of women's health (2002) · 2024Article
- Currently Available Treatment Modalities for Uterine Fibroids.Medicina (Kaunas, Lithuania) · 2024Review
- Messenger RNA Therapy for Female Reproductive Health.Molecular pharmaceutics · 2024Review
- Article
- Cysteine-rich intestinal protein 1 is a novel surface marker for human myometrial stem/progenitor cells.Communications biology · 2023Article
- Cysteine-Rich Intestinal Protein 1 is a Novel Surface Marker for Myometrial Stem/Progenitor Cells.bioRxiv : the preprint server for biology · 2023Article
- Use of oral GnRH antagonists combined therapy in the management of symptomatic uterine fibroids.Facts, views & vision in ObGyn · 2023Article
- Race, class, caste, disability, sterilisation and hysterectomy.Medical humanities · 2023Article
- Short- and long-term evaluation of disease-specific symptoms and quality of life following uterine artery embolization of fibroids.Insights into imaging · 2022Article
- A Call-to-Action for Clinicians to Implement Evidence-Based Best Practices When Caring for Women with Uterine Fibroids.Reproductive sciences (Thousand Oaks, Calif.) · 2022Article
- Current approaches to overcome the side effects of GnRH analogs in the treatment of patients with uterine fibroids.Expert opinion on drug safety · 2022Review
- An evaluation of relugolix/estradiol/norethindrone acetate for the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.Expert opinion on pharmacotherapy · 2022Article
- Uterine fibroids - Causes, impact, treatment, and lens to the African perspective.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uterine fibroids are the most common gynecological disorder, classically requiring surgery when symptomatic. Although attempts at finding a nonsurgical cure date back to centuries, it is only around the middle of the last century that serious attempts at a medical treatment were carried out. Initially, both progestins and estrogen-progestin combinations have been utilized, although proof of their usefulness is lacking. A major step forward was achieved when peptide analogs of the GnRH were introduced, first those with superagonist properties and subsequently those acting as antagonists. Initially, the latter produced side effects preventing their routine utilization; eventually, this problem was overcome following the synthesis of cetrorelix. Because both types of analogs produce hypoestrogenism, their use is limited to a maximum of 6 months and, for this reason, today they are utilized as an adjuvant treatment before surgery with overall good results. Over the last decade, new, nonpeptidic, orally active GnRH-receptor blockers have also been synthesized. One of them, Elagolix, is in the early stages of testing in women with fibroids. Another fundamental development has been the utilization of the so-called selective progesterone receptor modulators, sometimes referred to as "antiprogestins". The first such compound to be applied to the long-term treatment of fibroids was Mifepristone; today, this compound is mostly used outside of Western Countries, where the substance of choice is Ulipristal acetate. Large clinical trials have proven the effectiveness of Ulipristal in the long-term medical therapy of fibroids, although some caution must be exercised because of the rare occurrence of liver complications. All selective progesterone receptor modulators produce unique endometrial changes that are today considered benign, reversible, and without negative consequences. In conclusion, long-term medical treatment of fibroids seems possible today, especially in premenopausal women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.